Is Kisspeptin-54 legal in the United Kingdom?

Genuinely good randomised human evidence, all of it about triggering egg maturation in IVF: oocyte maturation in 95% of 60 women at high risk of ovarian hyperstimulation syndrome, with no moderate, severe or critical cases. Chronic dosing causes tachyphylaxis, a randomised trial found no effect on anxiety, and chronic subcutaneous dosing caused testicular degeneration in adult male rats.

Kisspeptin-54 is one of the better-evidenced compounds on this site, and the evidence points somewhere very specific that has almost nothing to do with how it is sold. It is the 54 residue product of the KISS1 gene, acting at KISS1R upstream of GnRH neurons.

Mechanism: Demonstrated in humans, not proposed. Kisspeptin-54 binds KISS1R, formerly GPR54, on hypothalamic GnRH neurons, triggering release of an endogenous pool of GnRH, which drives pituitary luteinising hormone and follicle-stimulating hormone secretion.

Regulatory history: Investigational. No approved kisspeptin product exists in any jurisdiction. The IVF trigger work is phase 2 and has not been taken to a registrational phase 3 programme.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Kisspeptin-54 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.